Literature DB >> 12806589

The renin-angiotensin-aldosterone system and Alzheimer s disease?

Patrick G Kehoe1.   

Abstract

Epidemiological studies from the last decade have begun to produce evidence that the perceived joint occurrence of vascular disease and Alzheimer's disease (AD), both common elderly disorders more often believed to occur by chance due to their high prevalence, may now actually have a more pathological significance. The following review discusses some of this evidence and the implications for cognitive decline and the development of AD and how a well-known cardiovascular risk factor gene, the apolipoprotein E (APOE) gene, plays a significant role in the molecular genetics of AD. It also introduces and discusses recent and compelling evidence for the involvement of another well-known cardiovascular risk factor gene, the angiotensin-converting enzyme (ACE1) gene, in the pathogenesis of AD. This role is suggested in terms of recent molecular genetic association evidence implicating the ACE1 insertion/deletion (indel) polymorphism, a more recent large haplotype study that greatly extends the ACE1 indel evidence and incorporates knowledge accrued from previous cardiovascular disease-focused ACE1 haplotype studies. Finally, this paper discusses very recent biological evidence that further supports a role for ACE1 and hypothesises a number of readily testable mechanisms by which the ACE1 enzyme and other components of the renin-angiotensin-aldosterone system may be implicated in increased risk and/or the progression of AD.

Entities:  

Mesh:

Year:  2003        PMID: 12806589     DOI: 10.3317/jraas.2003.017

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  13 in total

1.  No association of angiotensin I converting enzyme I/D polymorphism with domain-specific cognitive function in aged men without dementia.

Authors:  Mu-En Liu; Shih-Jen Tsai; Ti Lu; Cheng-Jee Hong; Ming-Chao Chen; Shoa-Lin Lin; Heng-Liang Yeh; Yan-Chiou Ku
Journal:  Neuromolecular Med       Date:  2011-08-11       Impact factor: 3.843

2.  Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Linda Ferrington; J Scott Miners; Laura E Palmer; Susan M Bond; Joanne E Povey; Paul At Kelly; Seth Love; Karen J Horsburgh; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2011-02-05       Impact factor: 4.060

3.  Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function.

Authors:  Santoshkumar Tota; Kashif Hanif; Pradeep Kumar Kamat; Abul Kalam Najmi; Chandishwar Nath
Journal:  Psychopharmacology (Berl)       Date:  2012-02-24       Impact factor: 4.530

Review 4.  Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions.

Authors:  Mathilde Keck; Reda Hmazzou; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2019-05-21       Impact factor: 5.369

5.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

Authors:  Scott Miners; Emma Ashby; Shabnam Baig; Rachel Harrison; Hannah Tayler; Elizabeth Speedy; Jonathan A Prince; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2009-01-18       Impact factor: 4.060

Review 6.  Hypertension, RAS, and gender: what is the role of aminopeptidases?

Authors:  María Jesús Ramírez-Expósito; José Manuel Martínez-Martos
Journal:  Heart Fail Rev       Date:  2008-01-24       Impact factor: 4.214

7.  ACE polymorphism and use of ACE inhibitors: effects on memory performance.

Authors:  Jaqueline B Schuch; Pamela C Constantin; Vanessa K da Silva; Camila Korb; Daiani P Bamberg; Tatiane J da Rocha; Marilu Fiegenbaum; Alcyr de Oliveira; Luciana A Tisser; Fabiana M de Andrade
Journal:  Age (Dordr)       Date:  2014-04-04

8.  Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease.

Authors:  Patrick G Kehoe; Hagit Katzov; Niels Andreasen; Maragaret Gatz; Gordon K Wilcock; Nigel J Cairns; Juni Palmgren; Ulf de Faire; Anthony J Brookes; Nancy L Pedersen; Kaj Blennow; Jonathan A Prince
Journal:  Hum Genet       Date:  2004-02-17       Impact factor: 4.132

Review 9.  Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease.

Authors:  Seth Love; J Scott Miners
Journal:  Brain Pathol       Date:  2016-09       Impact factor: 6.508

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.